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Background: We investigated whether serum glycated albumin (GA) levels are related to coronary collateralization
in type 2 diabetic patients with chronic total occlusion.
Methods: Blood levels of GA and glycosylated hemoglobin (HbA1c) were determined in 317 diabetic and 117
non-diabetic patients with stable angina and angiographic total occlusion of at least one major coronary artery.
The degree of collaterals supplying the distal aspect of a total occlusion from the contra-lateral vessel was graded
as low (Rentrop score of 0 or 1) or high collateralization (Rentrop score of 2 or 3).
Results: For diabetic patients, GA (21.2 ± 6.5% vs. 18.7 ± 5.6%, P < 0.001) but not HbA1c levels (7.0 ± 1.1% vs. 6.8 ± 1.3%,
P = 0.27) was significantly elevated in low collateralization than in high collateralization group, and correlated inversely
with Rentrop score (Spearmen’s r = −0.28, P < 0.001; Spearmen’s r = −0.10, P = 0.09, respectively). There was a trend
towards a larger area under the curve of GA compared with that of HbA1c for detecting the presence of low
collateralization (0.64 vs. 0.58, P = 0.15). In non-diabetic patients, both GA and HbA1c levels did not significantly
differ regardless the status of coronary collateralization. In multivariable analysis, female gender, age > 65 years,
smoke, non-hypertension, duration of diabetes > 10 years, metabolic syndrome, eGFR < 90 ml/min/1.73 m2, and
GA > 18.3% were independently determinants for low collateralization in diabetic patients.
Conclusions: Increased GA levels in serum are associated with impaired collateral growth in type 2 diabetic
patients with stable angina and chronic total occlusion.
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Coronary collateralization is a physiological adaptive
response to transient or permanent occlusion of major
coronary arteries [1,2]. Well-developed coronary collaterals
contribute to a reduction of infarct size, preservation of left
ventricular function, and an improvement of survival in
patients with coronary artery disease [3-5]. However,
such a physiological response is significantly impaired in* Correspondence: rjshenweifeng@gmail.com
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stated.patients with type 2 diabetes, metabolic syndrome, and se-
vere atherosclerosis [6,7]. In a diabetic setting, an excessive
formation of advanced glycation endproducts (AGEs) and
reactive oxygen species (ROS) frequently causes a reduction
of endothelium-mediated dilation, while blockade of AGEs
restores ischemia-induced angiogenesis [8,9].
Glycated albumin (GA) - a predominant early Amadori-
type glycation protein in serum - serves as an alternative
measure of dysglycemia over approximately 2–3 weeks,
and is associated with the occurrence and severity of
atherosclerosis in diabetes [10-14]. In cellular experiment,
GA promotes inflammation via activation of NF-κB
pathway in endothelial cells, induces adhesion of monocytesd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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cell surface adhesion molecules, and stimulates vascular
smooth muscle cell proliferation [10]. It is also a prognostic
marker for diabetic patients undergoing coronary artery
stent implantation [14,15], and a risk factor of mortality
and morbidity for those receiving hemodialysis [16,17]. GA
could be also formed in a non-diabetic milieu triggered by
inflammatory reaction [7,10]. Based upon these findings,
it is reasonable to hypothesize that GA might exert a
deleterious effect on coronary collateralization in diabetic
patients. To verify this hypothesis, we analyzed serum
levels of GA in diabetic and non-diabetic patients with
stable angina and chronic coronary total occlusion. This
angiographic criterion of inclusion was used because a
severe coronary artery obstruction was a prerequisite for
spontaneous collateral recruitment [18]. We assessed
the degree of coronary collateralization according to the
Rentrop grading system [19] as this method is easy to
incorporate into the routine clinical practice. To the best
of our knowledge, there is no previous report referring to
the relation of Amadori-modified proteins and collateral
formation in such a unique cohort.
Methods
Study population
A total of 537 consecutive patients with stable angina
and chronic total occlusion (> 3 months) of at least one
major epicardial coronary artery between January 2009 and
July 2013 from the database of Shanghai Rui Jin Hospital
Percutaneous Coronary Intervention (PCI) Outcomes
Program were screened. Stable angina was diagnosed
according to the criteria recommended by the American
College of Cardiology/ American Heart Association [20].
The duration of coronary artery occlusion was estimated
from the date of occurrence of myocardial infarction in
the area of myocardium supplied by the occluded vessel,
from an abrupt worsening of existing angina pectoris, or
from information obtained from a previous angiogram.
The diagnosis of type 2 diabetes mellitus and dyslipidemia
were made according to the criteria of the American
Diabetes Association and Third Report of The National
Cholesterol Education Program (NCEP) [21,22]. Meta-
bolic syndrome was defined by the updated 2005 National
Cholesterol Education Program Adult Treatment Panel III
(NCEP ATP III) [23]. We used body mass index (BMI) ≥
25 kg/m2 as the cut point of obesity according to the cri-
teria of Asia-Oceania [24]. For the purpose of research,
patients who received PCI within the prior 3 months
(n = 41) or had a history of coronary artery bypass
grafting (n = 38) were excluded. We also excluded those
with chronic heart failure, pulmonary heart disease, malig-
nant tumor or immune system disorders (n = 19). Patients
with type 1 diabetes were excluded by measurement of
peptide C level (n = 5). The remaining 434 patients (317diabetics and 117 non-diabetics) were enrolled in this
cross-sectional study.
The protocol was approved by the Hospital Ethics
Committee and written informed consent was obtained
from all patients. Since the study did not involve any
intervention, it was not prospectively registered.
Coronary angiography
Coronary angiography was performed through the femoral
or radial approach. All angiograms were reviewed by two
experienced interventional cardiologists, according to
lesion classification scheme of the American College of
Cardiology/American Heart Association [25]. They were
blinded to study protocol and biochemical measurements,
and any difference in interpretation was resolved by a
third reviewer. The presence and degree of collaterals
supplying the distal aspect of a total coronary occlusion
from the contra-lateral vessel were graded on a 4-point
scale from 0 to 3 according to the Rentrop scoring system
[18]: zero = no collateral vessels; 1 = thread-like, poorly
opacified collaterals with faint visualization of the distal
vessel; 2 = moderately opacified collateral channels; 3 =
large, brightly filled collateral channels with immediate
visualization of the entire distal vessel > 10 mm. Patients
were then classified as low (Rentrop score of 0 and 1) and
high (Rentrop score of 2 and 3) coronary collateralization,
as in previous studies [26,27]. For those with more than
one total coronary occlusion, the vessel with the highest
collateral grade was chosen for analysis.
Biochemical measurement
Blood samples were collected at the day of angiography
in patients after an overnight fasting. All samples were
stored at −80 °C until analysis. Serum glucose, glycosyl-
ated hemoglobin (HbA1c), blood urea nitrogen, creatin-
ine, uric acid, and lipid profiles were measured with
standard laboratory techniques on a Hitachi 912 Analyzer
(Roche Diagnostics, Germany). Modified estimated glom-
erular filtration rate (eGFR) was calculated, as described
previously [28].
Serum GA levels were determined with an improved
bromocresolpurple method using Lucica™ glycated albu-
min-L assay kit (Asahi Kasei Pharma, Japan). The linear
range for this assay was 3.2-68.1% and the maximum inter-
assay coefficient of variation (CV) was < 3.0% [11,12,14].
Statistical analysis
Continuous variables are presented as mean and standard
deviation (SD), and categorical data are summarized
as frequencies or percentages. For categorical clinical
variables, differences between groups were evaluated with
the chi-square test followed by Bonferroni’s correction to
account for multiple comparisons. For continuous vari-
ables, the existence of a normal distribution was evaluated
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square-root transformations were performed on the con-
tinuous variables of non-normal distribution. Differences
among groups were analyzed by one-way analysis of
variance (ANOVA) or the Kruskal–Wallis analysis followed
by post-hoc analysis. Correlation between variables was
determined by the Spearman’s rho tests as appropriate.
Receiver operating characteristic (ROC) curve was plottedTable 1 Baseline characteristics and biochemical assessment
Non-diabetes
Collateralization Low High
Number of patients n = 22 n = 95
Female, n (%) 12 (54.5) 12 (12.6)
Age, y 68 ± 11.1 62.4 ± 10.4
Age > 65y 16 (72.7) 33 (34.7)
Body mass index, Kg/m2 25.3 ± 2.8 24.8 ± 3.0
Smoke, n (%) 8 (36.4) 47 (49.5)
Hypertension, n (%) 10 (45.5) 69 (72.6)
Dyslipidemia, n (%) 15 (68.2) 37 (38.9)
Systolic blood pressure, mm Hg 142.3 ± 18.3 139.6 ± 17.0
Diastolic blood pressure, mm Hg 86.4 ± 13.6 84.4 ± 8.1
Durration of diabetes, y / /
Fasting blood glucose, mmol/L 5.4 ± 0.7 5.0 ± 0.7
HbA1c,% 6.3 ± 0.3 6.3 ± 0.5
Glycated albumin,% 19.1 ± 4.6 18.4 ± 5.2
Triglyceride, mmol/L 1.8 ± 0.8 1.7 ± 0.8
Total cholesterol, mmol/L 3.9 ± 1.1 4.4 ± 1.1
HDL-C, mmol/L 0.9 ± 0.2 1.0 ± 0.3
LDL-C, mmol/L 2.4 ± 1.0 2.7 ± 0.9
Metabolic syndrome, n (%) 12 (54.5) 42 (44.2)
Blood urea nitrogen, mmol/L 5.1 ± 1.7 5.0 ± 2.0
Uric acid, mmol/L 354.5 ± 59.4 337.0 ± 83.7
Creatinine, μmol/L 85.2 ± 17.1 76.4 ± 22.3
eGFR, mL/min/1.73 m2 80.9 ± 24.3 104.3 ± 26.3
Number of significant CAD
1-vessel 8 (36.4) 19 (20.0)
2-vessel 9 (40.9) 46 (48.4)
3-vessel 5 (22.7) 30 (31.6)
Medication, n (%)
ACE inhibitors 7 (31.8) 33 (34.7)
β-blockers 11 (50.0) 28 (29.5)
Calcium channel blockers 7 (31.8) 20 (21.1)
Nitrates 5 (22.7) 35 (36.8)
Statins* 18 (81.2) 82 (86.3)
Anti-diabetic treatment 0 (0) 0 (0)
Data are mean ± SD or number (%). Abbreviations: ACE, angiotensin-converting enzy
A1c; HDL-C, high-density lipoprotein cholesterol; LDL-C, low- density lipoprotein chto assess the power of GA and HbA1c for detecting
low collateralization, and the area under the curve was
compared using the DeLong method. The independent
determinants for low collateralization were assessed by
multivariate logistic regression analysis, and the covar-
iates chosen to enter the multivariate analysis model
included age, gender, BMI, risk factors for coronary
artery disease, duration of diabetes, metabolic syndrome,in patients with chronic total occlusion
Diabetes
P value Low High P value
n = 118 n = 199
< 0.001 41 (34.7) 27 (13.6) < 0.001
0.03 66.5 ± 10.1 64.6 ± 11.1 0.12
0.001 76 (64.4) 80 (40.2) < 0.001
0.53 25.8 ± 3.4 25.1 ± 3.4 0.07
0.27 46 (39.0) 71 (35.7) 0.56
0.01 77 (65.3) 157 (78.9) 0.008
0.01 67 (56.8) 81 (40.7) 0.006
0.51 140.5 ± 18.7 139.9 ± 17.1 0.76
0.53 84.1 ± 10.4 84.3 ± 9.1 0.86
/ 8.8 ± 4.6 5.7 ± 3.4 < 0.001
0.03 5.9 ± 1.8 5.5 ± 1.5 0.049
0.86 7.0 ± 1.1 6.8 ± 1.3 0.27
0.54 21.2 ± 6.5 18.7 ± 5.6 < 0.001
0.49 1.9 ± 1.1 1.8 ± 1.2 0.36
0.08 4.5 ± 1.5 4.1 ± 1.2 0.009
0.10 1.0 ± 0.3 1.1 ± 0.3 0.10
0.15 2.8 ± 1.2 2.5 ± 1.0 0.045
0.38 106 (89.8) 148 (74.4) 0.001
0.82 5.3 ± 2.3 5.1 ± 1.6 0.40
0.36 353.3 ± 84.6 329.7 ± 77.4 0.01
0.08 89.7 ± 22.5 76.8 ± 23.7 < 0.001
< 0.001 80.5 ± 21.5 102.4 ± 24.1 < 0.001
0.25 0.30
30 (25.4) 38 (19.1)
40 (33.9) 82 (41.2)
48 (40.7) 79 (39.7)
0.80 63 (53.4) 106 (53.3) 0.98
0.07 44 (37.3) 78 (39.2) 0.74
0.28 32 (27.1) 51 (25.6) 0.77
0.21 69 (58.5) 127 (63.8) 0.34
0.89 98 (83.7) 166 (83.3) 0.99
/ 92 (78.0) 170 (85.4) 0.09
me; eGFR, estimated glomerular filtration rate; HbA1c, glycatedhemoglobin
olesterol *Statins: mainly simvastatin, pravastatin and atorvastatin.
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measurements. All analyses used 2-sided tests with an
overall significance level of alpha = 0.05, and were per-
formed with the SPSS 15.0 for Windows (SPSS, Inc.,
Chicago, IL, USA).
Results
Baseline characteristics and bio-measurements
Baseline demographic and clinical characteristics and
biochemical measurements are listed in Table 1. Both
diabetic and non-diabetic patients with low collateraliza-
tion were older and less hypertensive, but were females in
higher percentage and had higher fasting glucose and
more dyslipidemia, and renal impairment than those
with high collateralization (for all comparison, P < 0.05).
Metabolic syndrome was more common, and serum levels
of total cholesterol, low-density lipoprotein cholesterol,
and uric acid were significantly elevated in diabetic patients
with low collateralization.
Serum GA levels and coronary collateralization
GA levels (21.2 ± 6.5% vs. 18.7 ± 5.6%, P < 0.001) but not
HbA1c (7.0 ± 1.1% vs. 6.8 ± 1.3%, P = 0.27) were consist-
ently higher in diabetic patients with low collateralization
as compared with those who had high collateralization
(Table 1). This finding was persistent even after having the
group age-matched (P = 0.004 and P = 0.11, respectively).
Further statistics showed that subgroups stratified by
Rentrop score exhibited significant difference in GA levels
for diabetic patients (Figure 1), and GA but not HbA1c
correlated inversely with the degree of collateralization
categorized by Rentrop score after adjusting for age,
gender, BMI, risk factors for coronary artery disease
(including smoke, hypertension and dyslipidemia), multi-
vessel disease, and eGFR (Spearmen’s r = −0.28, P < 0.001;Figure 1 Relationship between serum levels of glycated
albumin and collateral flow grade in diabetic patients.Spearmen’s r = −0.10, P = 0.09, respectively). In contrast,
for non-diabetic counterparts, both GA and HbA1c levels
did not significantly differ regardless the status of coronary
collateralization and after having the group age-matched
(P = 0.96 and P = 0.80, respectively).
ROC curve analysis showed that there was a trend
towards a larger area under the curve of GA compared
with that of HbA1c (0.64 vs. 0.58, P = 0.15), and the cut-
off of GA > 18.3% was more sensitive than HbA1c > 7.0%
for detecting the presence of low collateralization in
diabetic patients (67% vs. 47%, Figure 2).
Multivariable analysis
Multivariate logistic regression analysis revealed that
in non-diabetic patients, female gender (P = 0.01), age >
65 years (P = 0.04), non-hypertension (P = 0.02), dyslipid-
emia (P = 0.02), and eGFR < 90 mL/min/1.73 m2 (P = 0.04)
were independently associated with low collateralization.
In diabetic patients, after adjusting for possible con-
founding factors including age, gender, BMI, risk factors
for coronary artery disease, duration of diabetes, metabolic
syndrome, impaired renal function, and multivessel disease,
GA > 18.3% but not HbA1c > 7% remained an independent
determinant for low collateralization (Figure 3).
Discussion
Coronary collateral circulation is an important prognostic
marker of ischemic heart disease [5]. This study is the first
to demonstrate that increased serum GA levels are
inversely associated with the degree of coronary collateral
formation in diabetic patients with stable angina andFigure 2 ROC curve for glycated albumin (GA) and glycated
hemoglobin (HbA1c) in detecting the presence of low
collateralization in diabetic patients.
Figure 3 Relative risk for low collateralization in diabetic patients. Data are ORs, with 95% CI in parentheses. (eGFR, estimated glomerular
filtration rate).
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pathophysiology of impaired collateral growth in diabetes.
Accumulating evidence suggests that diabetes may
exert a deleterious effect on several components necessary
for collateral development, including pro-angiogenic
growth factors, endothelial function, redox state of the
coronary circulation, intracellular signaling, leukocytes
and bone marrow-derived progenitor cells [6]. Previous
studies have shown that GA induces endothelial dysfunc-
tion, and produces pro-inflammatory effects in macro-
phages through ROS augmentation [6,29-32]. Moreover,
this glycated protein reflecting poor glycemic control
impairs angiogenic function and elicits apoptosis of
endothelial progenitor cells (EPCs) [33-37]. Thus, these
observations support a notion that GA may be either a
risk factor or a marker for poor collateral growth in
diabetes.
In the present study, at least mildly impaired renal
function (eGFR < 90 ml/min/1.73 m2) was found to be a
strong independent risk factor for low collateralization
in patients with stable angina and chronic total occlu-
sion, particularly in those with diabetes. This finding
may be partly related to a high occurrence rate of chronic
kidney disease in diabetic and non-diabetic patients with
coronary artery disease, which is supported by prior
reports [26,38,39]. The direct and indirect effects of
uremic toxins cause ROS-mediated endothelial dysfunc-
tion and inhibit proliferation of EPCs [40], combined with
pathophysiology of diabetes including the effect of GA,
eventually lead to reduced collateral growth in patients
with chronic kidney disease.
Notably, the present study showed that GA but not
HbA1c levels were higher in diabetic patients with low
coronary collateralization, and that GA levels were more
sensitive for detecting low coronary collateralization as
compared with HbA1c in diabetic patients. These results
are consistent with previous observations including ours,
indicating that GA is superior to HbA1c in evaluating
vasculopathies in diabetic patients with certain specificdisorders such as coronary artery disease and renal
dysfunction [41].Limitations
We recognize that there are several limitations in our
study. First, the study is cross-sectional for the point of
coronary collateral investigation, thereby allowing us
to detect association, not to predict outcome. Second,
we evaluated the presence and degree of collaterals
according to the Rentrop scoring system. Coronary
collaterals may be more accurately assessed by collateral
flow index with simultaneous measurement of aortic
pressure and the distal pressure within the occluded
segment of the culprit coronary artery [1]. Nevertheless,
angiographic assessment of coronary collaterals is easy
to incorporate into the routine clinical practice [19,26].
Third, elevated serum GA levels and low coronary
collateralization may be also caused by the presence of
metabolic syndrome and not diabetes alone. Finally,
further large-scale studies with molecular experiments
are required to clarify the mechanisms of GA effect on
coronary collateralization.Conclusions
The present study has demonstrated an association be-
tween increased GA levels in serum and reduced cor-
onary collaterals in diabetic patients with stable angina
and chronic total occlusion. These findings might offer a
rationale in an effort to improve clinical outcomes in this
unique diabetic cohort with aggressive intervention of
AGEs and inflammatory process.Source of funding
This study was supported by the National Natural Science
Foundation of China (81070240 and 81070178) and
Science Technology Committee of Shanghai Municipal
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